<DOC>
	<DOC>NCT00140400</DOC>
	<brief_summary>The objective of this study is to evaluate the safety and efficacy of a prime-boost dose schedule of Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) as measured by standard toxicity evaluation, changes in PSA, and tumor responses. Additional objectives are to measure the time to PSA and/or clinical disease progression as well as local and systemic immune responses to the vaccine.</brief_summary>
	<brief_title>Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Diagnosis of adenocarcinoma prostate cancer Prostate cancer deemed to be unresponsive or refractory to hormone therapy An ECOG performance status of 0 or 1 Transitional cell, small cell, neuroendocrine, or squamous cell prostate cancer Previous chemotherapy, biological or immunotherapy for cancer Previous gene therapy for cancer Significant cancer related pain</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Advanced prostate cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Hormone-refractory</keyword>
	<keyword>GVAX</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Allogeneic cells</keyword>
</DOC>